A Phase 3 interventional study of Baloxavir Marboxil and Placebo to Baloxavir Marboxil in Influenza, sponsored by Shionogi. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.
Among the 18 studies testing baloxavir in Influenza, Human, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 12 in phase 3, and was the 2nd registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
Dre Pauline Vetter · Sites in Switzerland
Ages 18+
Hoffmann-La Roche · Sites in United States, Bulgaria, Poland and 1 more country
Ages 3 wk–11 yrs
University of Oxford · Sites in Brazil, Laos, Nepal and 1 more country
Ages 18–60
By country, each count listing its studies:
baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 13 · Phase 4 3
First in 2016; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,184 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 483 across the 18 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 8 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies testing baloxavir in Influenza, Human that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06653569Phase 3Dre Pauline VetterEfficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment) | 2027-04 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT05648448University of OxfordA Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | 2027-01-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies testing baloxavir in Influenza, Human, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a diagnosis of influenza confirmed by all of the following:
i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)
The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:
Patients will be considered at high risk* of influenza complications due to the presence of at least 1 of the following inclusion criteria:
Exclusion Criteria:
Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of \< 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Drug: Baloxavir Marboxil · Drug: Placebo to Oseltamivir
Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
Drug: Placebo to Baloxavir Marboxil · Drug: Oseltamivir
Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
Drug: Placebo to Baloxavir Marboxil · Drug: Placebo to Oseltamivir
Tablets taken orally
Also known as: S-033188, Xofluza®
Matching tablets taken orally
Capsules taken orally
Also known as: Tamiflu®
Matching placebo capsules taken orally
Time to Improvement of Influenza Symptoms
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.
Time frame: From Day 1 pretreatment up to Day 14
Percentage of Participants With Positive Influenza Virus Titer at Each Time Point
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.
Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point
Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.
Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9.
Change From Baseline in Virus Titer at Each Time Point
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point
Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).
Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer
This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
Time frame: Day 1 to Day 9
Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA
This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
Time frame: Day 1 to Day 9
Time to Cessation of Viral Shedding Determined by Virus Titer
Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
Time frame: Day 1 to Day 9
Time to Cessation of Viral Shedding Determined by Virus RNA
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
Time frame: Day 1 to Day 9
Percentage of Participants Whose Symptoms Were Improved at Each Time Point
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity * Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment
Time to Alleviation of Symptoms
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Time to Improvement of the Four Systemic Symptoms
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.
Time frame: Initiation of study treatment up to Day 14
Time to Improvement of the Three Respiratory Symptoms
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Time to Resolution of Fever
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
Time frame: Initiation of study treatment up to Day 14
Percentage of Participants Reporting Normal Temperature at Each Time Point
Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.
Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment
Body Temperature at Each Time Point
Participant's self-measured axillary temperature using an electronic thermometer.
Time frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment
Time to Improvement of Individual Symptoms
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours: * Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours. Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.
Time frame: Initiation of study treatment up to Day 14
Time to Return to Preinfluenza Health Status
Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and condition\]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
Time frame: Baseline to Day 14
Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection
The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).
Time frame: Day 2 to Day 22
Percentage of Participants With Influenza-related Complications
Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.
Time frame: Day 1 to Day 22
Percentage of Participants With Adverse Events (AEs)
Time frame: From first dose of study drug to Day 22
This was a multicenter study conducted at 551 sites, including 242 sites in the United States, 142 sites in Japan, 48 sites in APAC (including Australia, New Zealand, Philippines, and South Korea), 98 sites in Europe (Belgium, Germany, Hungary, Latvia, Poland, Romania, and Spain), and 21 sites in South Africa.
| Milestone | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Started | 730 | 729 | 725 |
| Received study drug | 728 | 728 | 722 |
| Intention to treat infected population | 388 | 386 | 389 |
| Completed | 697 | 695 | 683 |
| Not completed | 33 | 34 | 42 |
| Withdrew: Adverse event | 6 | 7 | 3 |
| Withdrew: Failed inclusion/exclusion criteria | 0 | 0 | 3 |
| Withdrew: Protocol deviation | 5 | 3 | 3 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 13 | 13 | 21 |
| Withdrew: Lost to follow-up | 7 | 5 | 5 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Miscellaneous | 2 | 4 | 6 |
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Improvement of Influenza Symptoms | 73.2 (67.2 to 85.1) | 102.3 (92.7 to 113.1) | 81.0 (69.4 to 91.5) |
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.
| percentage of participants | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Day 2 | 58.6 (53.2 to 63.9) | 86.9 (82.9 to 90.3) | 86.9 (82.9 to 90.3) |
| Day 3 | 31.7 (26.7 to 36.9) | 72.7 (67.6 to 77.4) | 60.0 (54.6 to 65.2) |
| Day 4 | 18.5 (12.2 to 26.2) | 50.0 (40.8 to 59.2) | 33.1 (24.9 to 42.1) |
| Day 5 | 16.0 (12.1 to 20.4) | 30.7 (25.7 to 36.1) | 20.4 (16.2 to 25.2) |
| Day 6 | 4.3 (1.4 to 9.9) | 16.0 (9.6 to 24.4) | 11.4 (6.0 to 19.1) |
| Day 9 | 2.8 (1.3 to 5.2) | 5.3 (3.1 to 8.3) | 0.9 (0.2 to 2.7) |
Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.
| percentage of participants | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Day 2 | 96.0 (93.4 to 97.7) | 96.3 (93.8 to 97.9) | 96.0 (93.5 to 97.7) |
| Day 3 | 92.5 (89.4 to 95.0) | 95.4 (92.8 to 97.3) | 95.1 (92.4 to 97.1) |
| Day 4 | 86.5 (79.9 to 91.5) | 91.0 (85.1 to 95.1) | 86.4 (79.6 to 91.6) |
| Day 5 | 84.9 (80.8 to 88.4) | 88.6 (84.9 to 91.7) | 86.1 (82.2 to 89.5) |
| Day 6 | 71.8 (63.2 to 79.3) | 78.0 (69.7 to 85.0) | 71.8 (62.7 to 79.7) |
| Day 9 | 54.5 (49.3 to 59.8) | 64.9 (59.7 to 69.8) | 57.7 (52.3 to 62.9) |
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
| log₁₀[TCID₅₀/mL] | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Day 2 | -3.36 ± 2.21 | -1.25 ± 2.27 | -1.76 ± 2.20 |
| Day 3 | -3.92 ± 2.22 | -2.99 ± 2.55 | -3.26 ± 2.50 |
| Day 4 | -3.99 ± 2.00 | -3.79 ± 2.75 | -3.75 ± 2.26 |
| Day 5 | -4.32 ± 2.16 | -4.38 ± 2.31 | -4.41 ± 2.12 |
| Day 6 | -4.07 ± 2.05 | -4.68 ± 2.22 | -4.39 ± 1.97 |
| Day 9 | -4.53 ± 2.11 | -4.91 ± 2.08 | -4.78 ± 2.07 |
Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).
| log₁₀ virus particles/mL | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Day 2 | -1.13 ± 1.20 | -0.62 ± 1.34 | -0.76 ± 1.18 |
| Day 3 | -2.09 ± 1.45 | -1.57 ± 1.66 | -1.77 ± 1.45 |
| Day 4 | -2.77 ± 1.42 | -2.09 ± 1.84 | -2.34 ± 1.63 |
| Day 5 | -3.09 ± 1.58 | -2.77 ± 1.67 | -3.04 ± 1.46 |
| Day 6 | -3.33 ± 1.48 | -3.19 ± 1.77 | -3.41 ± 1.38 |
| Day 9 | -3.89 ± 1.51 | -3.78 ± 1.65 | -3.99 ± 1.39 |
This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
| log₁₀[TCID₅₀/mL]*hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer | -727.7 ± 367.2 | -660.2 ± 372.3 | -695.5 ± 360.5 |
This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
| log₁₀ virus particles/mL*hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA | -490.9 ± 249.3 | -434.9 ± 269.3 | -482.2 ± 233.2 |
Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Cessation of Viral Shedding Determined by Virus Titer | 48.0 (NA to NA) | 96.0 (NA to NA) | 96.0 (72.0 to 96.0) |
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Cessation of Viral Shedding Determined by Virus RNA | 216.0 (192.0 to 240.0) | 240.0 (216.0 to 312.0) | 216.0 (216.0 to 240.0) |
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity * Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
| percentage of participants | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| 12 hours | 9.1 (6.1 to 13.0) | 8.6 (5.7 to 12.3) | 8.1 (5.3 to 11.8) |
| 24 hours | 18.8 (14.9 to 23.2) | 14.2 (10.8 to 18.3) | 19.6 (15.7 to 24.1) |
| 36 hours | 33.9 (28.6 to 39.5) | 21.1 (16.6 to 26.1) | 31.0 (25.8 to 36.6) |
| 48 hours | 38.0 (33.0 to 43.2) | 28.8 (24.2 to 33.7) | 39.9 (34.9 to 45.2) |
| 72 hours | 56.0 (50.7 to 61.2) | 41.8 (36.6 to 47.1) | 56.0 (50.6 to 61.3) |
| 96 hours | 65.9 (60.7 to 70.9) | 53.4 (47.9 to 58.8) | 61.1 (55.8 to 66.3) |
| 120 hours | 72.3 (67.4 to 76.9) | 64.6 (59.3 to 69.7) | 72.4 (67.2 to 77.1) |
| 144 hours | 78.1 (73.4 to 82.3) | 69.6 (64.4 to 74.4) | 77.6 (72.7 to 82.0) |
| 168 hours | 80.1 (75.5 to 84.2) | 72.7 (67.5 to 77.5) | 79.6 (74.8 to 83.8) |
| 192 hours | 83.6 (79.2 to 87.3) | 78.0 (73.2 to 82.3) | 85.6 (81.3 to 89.2) |
| 216 hours | 85.8 (80.1 to 90.3) | 78.7 (71.9 to 84.6) | 88.2 (82.5 to 92.5) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Alleviation of Symptoms | 77.0 (68.4 to 88.3) | 102.8 (93.2 to 113.4) | 85.6 (71.5 to 94.8) |
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Improvement of the Four Systemic Symptoms | 51.7 (45.0 to 55.4) | 66.8 (60.1 to 70.0) | 49.4 (44.2 to 56.8) |
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Improvement of the Three Respiratory Symptoms | 63.6 (55.9 to 68.2) | 87.8 (76.3 to 98.9) | 62.1 (54.0 to 69.1) |
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Resolution of Fever | 30.8 (28.2 to 35.4) | 50.7 (44.6 to 58.8) | 34.3 (30.0 to 38.9) |
Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.
| percentage of participants | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| 12 hours | 29.7 (24.9 to 34.9) | 24.6 (20.1 to 29.5) | 25.9 (21.3 to 30.8) |
| 24 hours | 51.1 (45.8 to 56.4) | 43.2 (38.1 to 48.5) | 54.3 (49.1 to 59.5) |
| 36 hours | 68.1 (62.9 to 73.0) | 47.4 (42.1 to 52.8) | 64.1 (58.8 to 69.2) |
| 48 hours | 77.4 (72.8 to 81.6) | 59.3 (54.1 to 64.3) | 76.4 (71.7 to 80.7) |
| 72 hours | 84.0 (79.6 to 87.7) | 71.7 (66.6 to 76.5) | 82.6 (78.0 to 86.6) |
| 96 hours | 87.5 (83.5 to 90.9) | 79.8 (75.0 to 84.0) | 85.8 (81.5 to 89.5) |
| 120 hours | 86.2 (82.0 to 89.8) | 86.6 (82.4 to 90.1) | 88.4 (84.3 to 91.7) |
| 144 hours | 90.0 (86.1 to 93.0) | 86.1 (81.9 to 89.7) | 87.4 (83.1 to 90.9) |
| 168 hours | 87.9 (83.8 to 91.2) | 88.1 (84.0 to 91.5) | 87.7 (83.4 to 91.2) |
| 192 hours | 89.0 (85.0 to 92.2) | 87.5 (83.3 to 91.0) | 90.5 (86.5 to 93.6) |
| 216 hours | 89.1 (85.1 to 92.3) | 89.9 (85.9 to 93.1) | 89.6 (85.7 to 92.8) |
Participant's self-measured axillary temperature using an electronic thermometer.
| °C | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| 12 hours | 37.39 ± 0.07 | 37.53 ± 0.07 | 37.43 ± 0.07 |
| 24 hours | 36.84 ± 0.06 | 37.02 ± 0.06 | 36.80 ± 0.06 |
| 36 hours | 36.58 ± 0.06 | 36.94 ± 0.06 | 36.62 ± 0.06 |
| 48 hours | 36.44 ± 0.06 | 36.77 ± 0.06 | 36.50 ± 0.06 |
| 72 hours | 36.30 ± 0.05 | 36.46 ± 0.05 | 36.29 ± 0.05 |
| 96 hours | 36.26 ± 0.05 | 36.35 ± 0.05 | 36.24 ± 0.05 |
| 120 hours | 36.26 ± 0.05 | 36.27 ± 0.05 | 36.21 ± 0.05 |
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours: * Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours. Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Cough | 47.3 (42.8 to 52.7) | 70.4 (56.5 to 79.5) | 47.5 (43.0 to 55.4) |
| Sore Throat | 40.2 (32.4 to 46.1) | 46.5 (39.0 to 53.5) | 39.3 (30.1 to 42.8) |
| Headache | 33.4 (29.1 to 40.5) | 43.9 (33.6 to 46.2) | 31.3 (28.6 to 37.0) |
| Nasal Congestion | 45.6 (37.4 to 54.3) | 57.7 (48.7 to 67.8) | 44.0 (36.4 to 50.3) |
| Feverishness or Chills | 28.3 (24.2 to 31.8) | 31.9 (28.6 to 41.2) | 29.1 (25.2 to 30.8) |
| Muscle or Joint Pain | 37.2 (31.5 to 41.6) | 44.9 (42.2 to 52.0) | 33.2 (30.2 to 39.5) |
| Fatigue | 41.3 (35.2 to 46.1) | 48.8 (42.7 to 55.4) | 43.2 (39.3 to 47.4) |
Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and condition\]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
| hours | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Time to Return to Preinfluenza Health Status | 126.4 (104.6 to 153.4) | 149.8 (124.7 to 175.7) | 126.9 (104.9 to 152.7) |
The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).
| percentage of participants | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection | 3.4 (1.8 to 5.7) | 7.5 (5.1 to 10.6) | 3.9 (2.2 to 6.3) |
Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.
| percentage of participants | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Any Complications | 2.8 (1.4 to 5.0) | 10.4 (7.5 to 13.8) | 4.6 (2.8 to 7.2) |
| Death | 0.0 (0.0 to 0.9) | 0.0 (0.0 to 1.0) | 0.3 (0.0 to 1.4) |
| Hospitalization | 0.8 (0.2 to 2.2) | 1.3 (0.4 to 3.0) | 1.0 (0.3 to 2.6) |
| Sinusitis | 0.3 (0.0 to 1.4) | 2.1 (0.9 to 4.0) | 0.5 (0.1 to 1.8) |
| Otitis media | 0.0 (0.0 to 0.9) | 0.8 (0.2 to 2.3) | 0.3 (0.0 to 1.4) |
| Bronchitis | 1.8 (0.7 to 3.7) | 6.0 (3.8 to 8.8) | 2.3 (1.1 to 4.3) |
| Pneumonia | 0.0 (0.0 to 0.9) | 0.8 (0.2 to 2.3) | 0.5 (0.1 to 1.8) |
| percentage of participants | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| Any adverse event (AE) | 25.1 | 29.7 | 28.0 |
| Fatal adverse events | 0.0 | 0.0 | 0.1 |
| Serious adverse events | 0.7 | 1.2 | 1.1 |
| AEs leading to withdrawal of study drug | 0.7 | 0.7 | 0.6 |
| Treatment-related adverse events (TRAEs) | 5.6 | 8.3 | 7.9 |
| Fatal treatment-related adverse events | 0.0 | 0.0 | 0.0 |
| Treatment-related serious adverse events | 0.0 | 0.3 | 0.3 |
| TRAEs leading to withdrawal of study drug | 0.3 | 0.3 | 0.4 |
Collected over All-cause mortality data are reported from Day 1 though Day 22. Adverse events are reported from the first dose of study drug through Day 22 (i.e. treatment-emergent adverse events).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baloxavir Marboxil | 1/730 (0.1%) | 5/730 (0.7%) | 70/730 (9.6%) |
| Placebo | 0/727 (0%) | 9/727 (1.2%) | 92/727 (12.7%) |
| Oseltamivir | 1/721 (0.1%) | 8/721 (1.1%) | 90/721 (12.5%) |
| Event | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 2/730 | 0/727 | 0/721 |
| PneumoniaInfections and infestations | 1/730 | 1/727 | 1/721 |
| Septic shockInfections and infestations | 0/730 | 0/727 | 1/721 |
| Vulval abscessInfections and infestations | 0/730 | 0/727 | 1/721 |
| Staphylococcal infectionInfections and infestations | 0/730 | 0/727 | 1/721 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/730 | 0/727 | 1/721 |
| Cerebral infarctionNervous system disorders | 0/730 | 0/727 | 1/721 |
| Arachnoid cystNervous system disorders | 0/730 | 0/727 | 1/721 |
| Cardiac failureCardiac disorders | 0/730 | 0/727 | 1/721 |
| HypotensionVascular disorders | 0/730 | 1/727 | 1/721 |
| Event | Baloxavir Marboxil | Placebo | Oseltamivir |
|---|---|---|---|
| NauseaGastrointestinal disorders | 20/730 | 28/727 | 34/721 |
| BronchitisInfections and infestations | 21/730 | 33/727 | 30/721 |
| DiarrhoeaGastrointestinal disorders | 20/730 | 21/727 | 23/721 |
| SinusitisInfections and infestations | 14/730 | 21/727 | 22/721 |
The Intention-to-treat Infected population includes all participants with a confirmed diagnosis of influenza virus infection who received study drug, and were enrolled at sites with Good Clinical Practice compliance. Confirmation of influenza virus infection was based on the results of reverse transcription polymerase chain reaction on Day 1.
| Age, Continuous(years) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| Mean | 52.3 ± 16.8 | 51.9 ± 16.7 | 51.1 ± 17.0 | 51.8 ± 16.8 |
| Age, Customized(Participants) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| ≥ 12 to ≤ 19 years | 19 | 17 | 22 | 58 |
| ≥ 20 to ≤ 29 years | 29 | 22 | 27 | 78 |
| ≥ 30 to ≤ 39 years | 42 | 58 | 44 | 144 |
| ≥ 40 to ≤ 49 years | 63 | 55 | 75 | 193 |
| ≥ 50 to ≤ 59 years | 83 | 101 | 83 | 267 |
| ≥ 60 to ≤ 64 years | 39 | 30 | 35 | 104 |
| ≥ 65 to ≤ 74 years | 85 | 76 | 78 | 239 |
| ≥ 75 years | 28 | 27 | 25 | 80 |
| Sex: Female, Male(Participants) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| Female | 195 | 206 | 198 | 599 |
| Male | 193 | 180 | 191 | 564 |
| Ethnicity (NIH/OMB)(Participants) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| Hispanic or Latino | 62 | 59 | 56 | 177 |
| Not Hispanic or Latino | 325 | 327 | 331 | 983 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 | 6 |
| Asian | 167 | 157 | 163 | 487 |
| Black or African American | 39 | 30 | 29 | 98 |
| White | 178 | 194 | 188 | 560 |
| Other | 3 | 3 | 6 | 12 |
| Weight(Participants) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| < 80 kg | 239 | 232 | 233 | 704 |
| ≥ 80 kg | 149 | 154 | 156 | 459 |
| Time to Treatment From Influenza Onset(Participants) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| ≥ 0 to ≤ 12 hours | 27 | 42 | 37 | 106 |
| > 12 to ≤ 24 hours | 151 | 150 | 119 | 420 |
| > 24 to ≤ 36 hours | 114 | 120 | 141 | 375 |
| > 36 to ≤ 48 hours | 95 | 74 | 92 | 261 |
| Missing | 1 | 0 | 0 | 1 |
| Influenza Virus Subtype Based on RT-PCR Assay(Participants) | Baloxavir Marboxil | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| A/H1N1pdm | 28 | 17 | 35 | 80 |
| A/H3 | 182 | 185 | 190 | 557 |
| B | 167 | 168 | 149 | 484 |
| Mixed infection | 4 | 5 | 5 | 14 |
| Other | 7 | 11 | 10 | 28 |
5 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Apr 2018, 15 months.
Results were first posted in Nov 2019, 1 year 6 months after primary completion. A results delay was requested in Apr 2019.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 15 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baloxavir